BLTE - BELITE BIO, INC

QQQ $ 586.42 $ -25.19 (-4.12 %)

DIA $ 458.76 $ -7.92 (-1.7 %)

SPY $ 653.73 $ -19.17 (-2.85 %)

TLT $ 89.29 $ 0.30 (0.34 %)

GLD $ 374.63 $ -0.55 (-0.15 %)

Previous Close

$ 120.365

Open

$ 119.22

Bid

$ 110.02 x 2

Ask

$ 116.00 x 4

Day's Range

$ 105.88 - $ 116.26

52 Week Range

$ 49.00 - $ 125.24

Volume

59,259

Average Volume

Market Cap

3.83B

Beta (5Y Monthly)

$ 0.04

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Mizuho Initiates Coverage On Belite Bio wi...
11/20/2025 16:11:16

Mizuho analyst Graig Suvannavejh initiates coverage on Belite Bio (NASDAQ:BLTE) with a Neutral rating and announces Price Ta...

Belite Bio Q3 EPS $(0.65) Misses $(0.45) E...
11/10/2025 13:03:13

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.45) ...

Earnings Scheduled For November 10, 2025
11/10/2025 11:12:02

Earnings Outlook For Belite Bio
11/07/2025 15:02:31

Reported Sunday, Belite Bio Receives Unite...
11/03/2025 07:58:11

Benchmark Maintains Buy on Belite Bio, Rai...
10/31/2025 14:08:06

Benchmark analyst Bruce D. Jackson maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $80 to $132.

Belite Bio Says Center For Drug Evaluation...
10/15/2025 12:12:53

NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025SAN DIEGO, Oct...

HC Wainwright & Co. Maintains Buy on Belit...
09/15/2025 11:44:02

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and lowers the price target from $100 ...

Belite Bio Completes Last Subject Visit In...
09/12/2025 12:07:46

Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug...

Belite Bio Announces $125M PIPE Financing ...
09/08/2025 12:07:44

Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Sol...

Belite Bio Q2 EPS $(0.50) Misses $(0.40) E...
08/11/2025 10:01:08

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.40) ...

Earnings Scheduled For August 11, 2025
08/11/2025 08:32:28

Belite Bio's Earnings Outlook
08/08/2025 14:07:37

Belite Bio Announces $15M Direct Offering ...
08/07/2025 12:13:28

HC Wainwright & Co. Reiterates Buy on Beli...
07/03/2025 11:02:05

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $100 price target.

Belite Bio Enrolls 500 Subjects Globally I...
07/02/2025 07:27:13

500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Aus...

dycom-industries-posts-upbeat-earnings-joins-weride-keysight-technologies-and-other-big-stocks-moving-higher-on-wednesday

Dycom Industries Posts Upbeat Earnings, Jo...
05/21/2025 14:11:45

Belite Bio Secures FDA Breakthrough Therap...
05/21/2025 07:18:15

Cantor Fitzgerald Reiterates Overweight on...
05/15/2025 15:24:04

Cantor Fitzgerald analyst Jennifer Kim reiterates Belite Bio (NASDAQ:BLTE) from Overweight to Overweight.

HC Wainwright & Co. Reiterates Buy on Beli...
05/15/2025 11:28:42

HC Wainwright & Co. analyst Yi Chen reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $100 price target.